Parkinson DiseasePhase 2FAIRPARKIINCT02655315
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease
A Phase 2 study testing Deferiprone in people with Parkinson Disease, run by University Hospital, Lille at 25 sites in 8 countries.
Trial summary
This study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinson's disease. Half of participants will receive the deferiprone to 15 mg / kg twice daily morning and evening (30mg / kg per day), while the other half will receive a placebo. The treatment lasts nine months. Read more about this study
- Who is it for?
- Ages Up to 80 years
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- Deferiprone
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 372 participants
- Where
- 25 sitesin 8 countries
- Study dates
- 9 Feb 2016to 22 Sep 2020
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 80 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Adult patients
- Parkinson's disease diagnosed according United Kingdom Parkinson's disease Society Brain Bank Clinical Diagnostic Criteria and based on the presence of at least two of the three cardinal features of the disease (rest tremor, bradykinesia and rigidity). If rest tremor is not present, subjects must have unilateral onset of symptoms.
- Treatment-naïve, i.e. the best population for assessing a disease-modifying effect without the interaction of dopaminergic treatment (no dopaminergic agonists, L-dopa, anticholinergics, monoamine oxidase B inhibitors (e.g. rasagiline) or deep brain stimulation).
- Patients covered by a Health Insurance System in countries where required by law
- Written informed consent dated and signed prior to the beginning of any procedures related to the clinical trial
Who cannot join
- Disease duration greater than 18 months.
- Patients with high frequency of comorbidity or vital risks that may reasonably impair life expectancy
- Subject with handicap required dopaminergic treatment at the inclusion and therefore likely not to bear 9 months without symptomatic treatment
- Hoehn and Yahr stage 3 or more.
- Significant cognitive impairment (a Mini Mental State Examination score <24 or an equivalent impairment on a similar scale) or dementia diagnosed in accordance with the Movement Disorders Society criteria (Emre et al., 2007).
- Atypical or secondary parkinsonism (supranuclear palsy, multisystem atrophy, etc.) or anomalies on MRI suggestive of vascular involvement or significant cortical or subcortical atrophy (i.e. atypical for Parkinson's Disease).
Show all 28Show fewer
- Progressing axis I psychiatric disorders (psychosis, hallucinations, substance addiction, bipolar disorder, or severe depression), in accordance with the Diagnostic and Statistical Manual of Mental Disorders.
- Subjects undergoing brain stimulation.
- Positive Human Immunodepression Virus serology.
- Hypersensitivity to deferiprone.
- Patients with agranulocytosis or with a history of agranulocytosis.
- Patients taking a treatment at risk of agranulocytosis (clozapine, Closaril®/Leponex®).
- Patients with anaemia (regardless of the latter's aetiology) or a history of another haematological disease. Haemochromatosis is not an exclusion criterion.
- Pregnant or breastfeeding women or women of childbearing potential not taking highly effective contraception.
- Kidney or liver failure.
- Other serious diseases.
- Inability to provide informed consent.
- Participation in another clinical trial with investigational medicinal product within 3 months prior to inclusion in the study
- Patient who has suffered mild or moderate depressive episode and isn't in remission and on a stable medication for at least 8 weeks
- Patient > 130k
- Exclusion criteria for the biomarker study and the ancillary study (i) Magnetic Resonance Imaging:
- Subjects for whom Magnetic Resonance Imaging is contraindicated (metal objects in the body, severe claustrophobia, pacemaker, incompatible surgical material).
- Very severe rest tremor, which could induce Magnetic Resonance Imaging artefacts.
- Lumbar puncture:
- Blood coagulation disorders, antiplatelet drugs or anticoagulants.
- Intracranial hypertension. (iii) Contraindications to nitrous oxide:
- Ventilation with Fraction of inspired Oxygen >50%, emphysema or pneumothorax
- Altered states of consciousness, non-cooperative patient (need to stop the nitrous oxide)
Trial locations and contacts
25 sites in 8 countries.
25 sites in 8 countries
France8 sites
CHU Pellegrin
Bordeaux
Hôpital Wertheimer
Bron
Hôpital Montpied
Clermont-Ferrand
Hôpital Salengro, CHRU
Lille
CHU la TIMONE
Marseille
AP-HP, Hôpital Pitié-Salpêtrière
Paris
CHU de Strasbourg, Hôpital de Hautepierre
Strasbourg
Chu Purpan
Toulouse
Germany3 sites
University Hospital, Saarland University
Homburg
Christian-albrechts universität zu kiel
Kiel
Klinik und Poliklinik für Neurologie der Universitätsmedizin Rostock
Rostock
Portugal3 sites
Centro Hospitalar e universitario de Coimbra
Coimbra
Centro Hospitalar do Alto Ave
Guimarães
Centro Hospitalar Lisboa Norte
Lisbon
Spain3 sites
Hospital Clinic Universitari de Barcelona
Barcelona
Hospital de Bellvitge
Barcelona
Hospital de la Santa Creu i Sant Pau
Barcelona
United Kingdom3 sites
Cambridge University Hospital
Cambridge
University of Glasgow
Glasgow
Newcastle University
Newcastle
Netherlands2 sites
Acadamic central center, Amsterdam
Amsterdam
Radboud university medical center
Nijmegen
About this study
Official title: Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"
This study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinson's disease. Half of participants will receive the deferiprone to 15 mg / kg twice daily morning and evening (30mg / kg per day), while the other half will receive a placebo. The treatment lasts nine months.
Read the detailed description
This is the new concept of "conservative iron chelation". We recently demonstrated (for the first time) the feasibility, efficacy and acceptability of the conservative iron chelation approach in pilot translational studies in Parkinson's disease with a prototype drug: deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) (in the FAIR-PARK-I project led by the applicant and funded by French Ministry of Health). The only available blood-brain-barrier-permeable iron chelator deferiprone is approved for treating systemic iron overload in transfused patients with thalassemia. Deferiprone has been on the European Union market since 1999, with a favourable risk/benefit balance at dose of 75 to 100 mg/kg/day. The investigators shall adopt a repositioning strategy by using deferiprone at a lower dose of 30 mg/kg/day in this new indication for local iron overload in Parkinson's disease. Deferiprone will be the first-in-class drug for this novel therapeutic strategy. On the basis of the preclinical and clinical data from (FAIR-PARK-I), the present (FAIR-PARK-II) project should constitute a model for future cytoprotection strategies in neurodegenerative diseases; if deferiprone treatment is associated with significant slower disease progression, it would be the first non-dopaminergic drug to have a proven disease-modifying effect in Parkinson's disease.
- Conditions
- Parkinson Disease
- Being tested
- Deferiprone, Placebo
- Keywords
- Parkinson, Deferiprone, Chelation
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DeferiproneDrug
Also called active drug
15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
PlaceboDrug
Also called harmless pill, inactive drug
the placebo twice daily morning and evening. The treatment lasts nine months
| Study group | Role | What they receive |
|---|---|---|
| DEFERIPRONE | Active comparator | Half of participants will receive the deferiprone (DFP) to 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months. Receives: Drug: Deferiprone |
| PLACEBO | Placebo comparator | Half of participants will receive the placebo twice daily morning and evening. The treatment lasts nine months. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Global effect (symptomatic and disease modifying effects) on motor and non motor handicap
the change in the total Movement Disorders Society-Unified Parkinson Disease Rating Scale score between baseline and 36 weeks (i.e. the end of the placebo-controlled phase for analysis of both disease-modifying and symptomatic effects)
Measured: at 36 weeks
Secondary outcomes (12)
Disease-modifying effect on motor and non motor handicap
It will be measured as the changes in the overall Movement Disorders Society-Unified Parkinson Disease Rating Scale score between baseline and week 40 (i.e. the end of the one-month post-treatment monitoring period), to analyse the disease-modifying effect without bias from the symptomatic effect of ongoing deferiprone treatment) on the study population
Measured: baseline, at 40 weeks
Effect of the motor symptoms
The effect of the motor symptoms will be analysed as the change in the subscale part III of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score
Measured: baseline, at 12, 36 and 40 weeks
Quality of life and autonomy by PDQ-39 score
It will be analyzed as the change in the Parkinson's Disease Quality of Life (PDQ-39, via a 39-item self-questionnaire)
Measured: baseline, at 36 and 40 weeks
Quality of life and autonomy by Clinical Global Impression score
the Clinical Global Impression scored by the examiner and the patient
Measured: baseline, at 36 and 40 weeks
Health economics assessment
will be performed via a specific questionnaire provides a simple descriptive profile and a single index value for health status
Measured: baseline, at 36 and 40 weeks
EQ-5D questionnaire
the questionnaire provides a simple descriptive profile and a single index value for health status.
Measured: baseline, at 36 and 40 weeks
Safety criteria
All the safety concerns will be listed in a table with the number of patients, the type the severity and the time of occurrence for
- adverse events
- neutropenia (weekly complete blood count)
- agranulocytosis (weekly complete blood count)
- anemia (weekly complete blood count)
- iron metabolism abnormalities (haemoglobin, serum iron, ferritinemia, transferrin, total binding capacity, transferrin saturation coefficient, 24-hour urine iron).
- Standard biological abnormalities (fasting glucose, urea, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and (for all sexually active, fertile females) urine pregnancy tests.
- Abnormal physical examination (including vital signs, bodyweight, electrocardiogram and blood pressure)
Measured: 40 weeks
Effect on overall cognitive status
Measured by the score in the Montreal Cognitive Assessment
Measured: baseline, at 12, 36 and 40 weeks
Effect on gait disorders
Measured by the Stand Walk Sit test
Measured: baseline, at 12, 36 and 40 weeks
Effect on daily living
The effect on daily living will be analysed as the change in the subscale part II (activities of daily living) of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score
Measured: baseline, at 12, 36 and 40 weeks
Effect on non-motor symptoms
The effect on non motor symptoms will be analysed as the change in the subscale part I (cognition and behavior) of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score
Measured: baseline, at 12, 36 and 40 weeks
Lack of occurrence of motor fluctuations
The lack of occurrence of motor fluctuations will be analysed on the subscale part IV of the Movement Disorders Society-Unified Parkinson Disease Rating Scale score
Measured: baseline, at 12, 36 and 40 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2016 (estimated)
- Study start9 Feb 2016
- Primary completion22 Sep 2020
- Study completion22 Sep 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by University Hospital, LilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 372 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Lille
- Sponsor type
- University, hospital or other
- Collaborators
- European Commission, ApoPharma
- Responsible party
- Sponsor
- Investigators
- David Devos, MD, PhD, Study chair, University Hospital, Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02655315
- Sponsor's protocol ID
- 2015_22
- Other IDs
- 2015-003679-31, Grant agreement No 633190, HP751, 2015
- Acronym
- FAIRPARKII
- Status last verified
- Mar 2021
- First submitted
- 7 Jan 2016
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Publications
Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Ruzicka E, Dusek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garcon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Trial of Deferiprone in Parkinson's Disease. N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254.
PubMed 36449420Streit WJ, Phan L, Bechmann I. Ferroptosis and pathogenesis of neuritic plaques in Alzheimer disease. Pharmacol Rev. 2025 Jan;77(1):100005. doi: 10.1124/pharmrev.123.000823. Epub 2024 Nov 22.
PubMed 39952690Mahoney-Sanchez L, Bouchaoui H, Ayton S, Devos D, Duce JA, Devedjian JC. Ferroptosis and its potential role in the physiopathology of Parkinson's Disease. Prog Neurobiol. 2021 Jan;196:101890. doi: 10.1016/j.pneurobio.2020.101890. Epub 2020 Jul 26.
PubMed 32726602Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D; FAIRPARK-II study group. Iron as a therapeutic target for Parkinson's disease. Mov Disord. 2018 Apr;33(4):568-574. doi: 10.1002/mds.27275. Epub 2018 Jan 30. No abstract available.
PubMed 29380903
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"
- ClinicalTrials.gov ID
- NCT02655315
- Acronym / sponsor ID
- FAIRPARKII / 2015_22
- Conditions
- Parkinson Disease
- Keywords
- Parkinson, Deferiprone, Chelation
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 372 participants (actual)
- Lead sponsor
- University Hospital, LilleUniversity, hospital or other
- Collaborators
- European Commission, ApoPharma
- Study start
- 9 Feb 2016 (actual)
- Primary completion
- 22 Sep 2020 (actual)
- Study completion
- 22 Sep 2020 (actual)
- First posted
- 14 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinson's disease. Half of participants will receive the deferiprone to 15 mg / kg twice daily morning and evening (30mg / kg per day), while the other half will receive a placebo. The treatment lasts nine months.
Detailed description
This is the new concept of "conservative iron chelation". We recently demonstrated (for the first time) the feasibility, efficacy and acceptability of the conservative iron chelation approach in pilot translational studies in Parkinson's disease with a prototype drug: deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) (in the FAIR-PARK-I project led by the applicant and funded by French Ministry of Health). The only available blood-brain-barrier-permeable iron chelator deferiprone is approved for treating systemic iron overload in transfused patients with thalassemia. Deferiprone has been on the European Union market since 1999, with a favourable risk/benefit balance at dose of 75 to 100 mg/kg/day. The investigators shall adopt a repositioning strategy by using deferiprone at a lower dose of 30 mg/kg/day in this new indication for local iron overload in Parkinson's disease. Deferiprone will be the first-in-class drug for this novel therapeutic strategy. On the basis of the preclinical and clinical data from (FAIR-PARK-I), the present (FAIR-PARK-II) project should constitute a model for future cytoprotection strategies in neurodegenerative diseases; if deferiprone treatment is associated with significant slower disease progression, it would be the first non-dopaminergic drug to have a proven disease-modifying effect in Parkinson's disease.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| DEFERIPRONE | Active comparator | Drug: DeferiproneHalf of participants will receive the deferiprone (DFP) to 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months. |
| PLACEBO | Placebo comparator | Drug: PlaceboHalf of participants will receive the placebo twice daily morning and evening. The treatment lasts nine months. |
Who may qualify
- Ages
- Up to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Adult patients
- Parkinson's disease diagnosed according United Kingdom Parkinson's disease Society Brain Bank Clinical Diagnostic Criteria and based on the presence of at least two of the three cardinal features of the disease (rest tremor, bradykinesia and rigidity). If rest tremor is not present, subjects must have unilateral onset of symptoms.
- Treatment-naïve, i.e. the best population for assessing a disease-modifying effect without the interaction of dopaminergic treatment (no dopaminergic agonists, L-dopa, anticholinergics, monoamine oxidase B inhibitors (e.g. rasagiline) or deep brain stimulation).
- Patients covered by a Health Insurance System in countries where required by law
- Written informed consent dated and signed prior to the beginning of any procedures related to the clinical trial
Key exclusion criteria (28 listed)
- Disease duration greater than 18 months.
- Patients with high frequency of comorbidity or vital risks that may reasonably impair life expectancy
- Subject with handicap required dopaminergic treatment at the inclusion and therefore likely not to bear 9 months without symptomatic treatment
- Hoehn and Yahr stage 3 or more.
- Significant cognitive impairment (a Mini Mental State Examination score <24 or an equivalent impairment on a similar scale) or dementia diagnosed in accordance with the Movement Disorders Society criteria (Emre et al., 2007).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DeferiproneAlso: active drug15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months. | Drug | DEFERIPRONE |
| PlaceboAlso: harmless pill, inactive drugthe placebo twice daily morning and evening. The treatment lasts nine months | Drug | PLACEBO |
Primary outcome
Global effect (symptomatic and disease modifying effects) on motor and non motor handicap
Time frame: at 36 weeks
the change in the total Movement Disorders Society-Unified Parkinson Disease Rating Scale score between baseline and 36 weeks (i.e. the end of the placebo-controlled phase for analysis of both disease-modifying and symptomatic effects)
12 secondary outcomes
Disease-modifying effect on motor and non motor handicap
Time frame: baseline, at 40 weeks
Effect of the motor symptoms
Time frame: baseline, at 12, 36 and 40 weeks
Quality of life and autonomy by PDQ-39 score
Time frame: baseline, at 36 and 40 weeks
Quality of life and autonomy by Clinical Global Impression score
Time frame: baseline, at 36 and 40 weeks
Health economics assessment
Time frame: baseline, at 36 and 40 weeks
EQ-5D questionnaire
Time frame: baseline, at 36 and 40 weeks
Safety criteria
Time frame: 40 weeks
Effect on overall cognitive status
Time frame: baseline, at 12, 36 and 40 weeks
Effect on gait disorders
Time frame: baseline, at 12, 36 and 40 weeks
Effect on daily living
Time frame: baseline, at 12, 36 and 40 weeks
Effect on non-motor symptoms
Time frame: baseline, at 12, 36 and 40 weeks
Lack of occurrence of motor fluctuations
Time frame: baseline, at 12, 36 and 40 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Results publication: PubMed 36449420Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Ruzicka E, Dusek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garcon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Trial of Deferiprone in Parkinson's Disease. N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254.
- Derived from this study: PubMed 39952690Streit WJ, Phan L, Bechmann I. Ferroptosis and pathogenesis of neuritic plaques in Alzheimer disease. Pharmacol Rev. 2025 Jan;77(1):100005. doi: 10.1124/pharmrev.123.000823. Epub 2024 Nov 22.
- Derived from this study: PubMed 32726602Mahoney-Sanchez L, Bouchaoui H, Ayton S, Devos D, Duce JA, Devedjian JC. Ferroptosis and its potential role in the physiopathology of Parkinson's Disease. Prog Neurobiol. 2021 Jan;196:101890. doi: 10.1016/j.pneurobio.2020.101890. Epub 2020 Jul 26.
- Derived from this study: PubMed 29380903Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D; FAIRPARK-II study group. Iron as a therapeutic target for Parkinson's disease. Mov Disord. 2018 Apr;33(4):568-574. doi: 10.1002/mds.27275. Epub 2018 Jan 30. No abstract available.
- Website for informations on the Fairpark2 studyLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Devos, MD, PhD study chair
University Hospital, Lille
25 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Deferiprone in people with Parkinson Disease, run by University Hospital, Lille at 25 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 25 sites in France, Germany, Portugal, Spain, United Kingdom and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Global effect (symptomatic and disease modifying effects) on motor and non motor handicap (time frame: at 36 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02655315, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.